本次會議主要討論是否，以及如何，建立HTAi EU entity。
赴Glasgow參加Advancing Health Technology Assessment of Innovative Medical Devices and Digital Health Interventions: a Bilateral Perspective
2026-3-23~25 Glasgow
(經NotebookLM整理)
「推動創新醫療器材與數位健康介入之健康科技評估：雙邊觀點」（Advancing Health Technology Assessment of Innovative Medical Devices and Digital Health Interventions: a Bilateral Perspective）是一場由蘇格蘭愛丁堡皇家學會（RSE）與台灣國家科學及技術委員會（NSTC）共同資助舉辦的雙邊研究與創新工作坊。
本次會議於 2026年3月23日至25日 在英國格拉斯哥大學（University of Glasgow）的 The Ferguson Room 舉行。會議匯集了來自台灣與蘇格蘭的頂尖專家、學者、業界人士與政策制定者，旨在深化雙方在醫療器材與數位健康領域的合作與理解，並推動以證據為基礎的醫療保健決策。
以下為這次會議的完整重點描述：
1. 核心雙邊合作契機 (Scotland-Taiwan Opportunity) 會議強調了台灣與蘇格蘭在醫療科技上的互補優勢：
- 台灣的優勢在於強大的製造能力、電子資通訊（ICT）產業基礎，以及產品規模化的技術。
- 蘇格蘭的優勢則在於擁有完善的國民保健署（NHS）臨床試驗與驗證環境、強大的健康科技評估（HTA）證據生成能力、成熟的法規路徑，並能作為進入英國與歐洲市場的門戶。 透過結合雙方優勢，可以有效將創新技術轉化為具備全球競爭力的醫療產品，共同克服產品商業化過程中的「死亡之谷」（Valleys of death）。
2. 探討「兩道守門員」：法規批准與健康科技評估 (Regulation vs. HTA) 會議中多次強調，醫療科技要進入市場並獲取利潤，必須通過兩個不同標準的門檻：
- 第一道門（法規批准，如 FDA、CE、TFDA）： 著重於產品的安全性、效能與品質（是否安全？是否如預期運作？）。通過法規僅代表獲得市場准入（Market Authorisation），但不保證會被醫療機構採用。
- 第二道門（健康科技評估與健保給付，HTA / Reimbursement）： 著重於臨床成效、成本效益以及對整體醫療系統的價值（是否改善了患者預後？是否符合成本效益？）。許多 AI 或軟體醫療器材（SaMD）公司往往太晚意識到 HTA 的門檻遠高於一般法規批准。
3. 真實世界證據 (Real-World Evidence) 與資料整合 隨著數位健康與 AI 的發展，傳統臨床試驗已不足以應付需求。會議探討了如何利用**真實世界資料（Real-World Data, RWD）**來支持 HTA：
- 蘇格蘭擁有從1970年代起建立的國民健康追蹤數據庫，透過唯一的病患識別碼，可以連結初級與次級醫療數據。
- 格拉斯哥大學介紹了其「可信賴研究環境」（Trusted Research Environment, TRE），探討如何在保護資安隱私的框架下（Five Safes framework），讓研究人員安全地取用如醫療紀錄、醫學影像等敏感數據來進行演算法訓練與健康經濟學建模。
- 專家同時提醒，在使用大數據與 AI 時，需注意資料偏差（包括社會偏見、種族代表性不足）以及區分「相關性」與「因果關係」。
4. 實施科學 (Implementation Science) 與落地挑戰 即使技術通過法規與給付，如果在臨床場域難以使用，仍會面臨失敗。會議引用了 NASSS 框架（Non-adoption, Abandonment, Scale-up, Spread, Sustainability），強調技術在疾病狀況、科技本身、價值、採用者、組織架構等七個維度上的複雜性。例如，一個診斷心臟衰竭準確率極高的 AI 聽診器，如果無法順利融入醫師現有的電子病歷工作流程，最終仍會遭到棄用。
5. 豐富的產學創新案例分享 為期三天的議程中，來自兩地的團隊展示了多項創新案例：
- 數位健康與居家照護： 利用 Wi-Fi 訊號進行帕金森氏症患者的步態與動作監測；針對孩童語言遲緩的互動式 AI 語音治療軟體；以及結合科技與職能治療的居家生活優化平台（如 OOPS）和為高齡者設計的遊戲復健輔具（如結合任天堂 Switch 的控制套件）。
- 前線醫療創新： 以護理師需求為核心的創新設計（如磁吸式氧氣面罩固定器）；以及在缺乏基礎水電設施的地區，利用智慧型手機與 DNA 檢測技術進行傳染病（如瘧疾）的即時定點檢測（Point-of-care diagnostics）。
- 數位療法的經濟評估： 針對更年期婦女的數位認知行為療法（CBT），探討如何透過健康經濟模型證明其能縮短等待時間並改善醫療不平等的價值。
會議行程與交流形式： 這場工作坊包含了專題演講、專家座談、產業案例分析，以及分組的跨國合作討論。此外，大會也安排了實地參訪，包括詹姆斯·瓦特奈米製造中心（James Watt Nanofabrication Centre）與伊莉莎白女王醫院的健康創新中心（Queen Elizabeth Campus Health Innovation Hub），並透過晚宴（如於 Ubiquitous Chip 與 Hotel du Vin）進一步促進雙邊代表的實質交流與未來研究提案的成形。
20260320 「鬆綁核醫藥物法規、完善健保機制—維護神經內分泌腫瘤病友治療權益」公聽會
立法委員劉建國辦公室、立法院厚生會，與中華民國核醫學學會、台灣神經內分泌腫瘤病友關懷協會，共同於115年3月20日，在立法院群賢樓802會議室，為突破神經內分泌腫瘤（Neuroendocrine tumor,NET）的治療困境瓶頸，並針對現行健保制度與新興放射標靶療法的給付限制進行深度檢討，特邀集醫界專家、病友團體、政府官員召開公聽會。與會人員在公聽會中共同呼籲，政府應加速鬆綁核醫藥物法規、完善健保給付機制，導入國際標準治療，以確保病友治療權益與醫療體系永續發展。
輔仁大學數據科學中心蒲若芳執行長從醫療科技評估角度指出，目前制度存在三大問題，包括對新興治療方法敏感度不足、適應症限縮邏輯不一致，以及審查決策透明度不足，且進一步說明：「醫療科技評估（Health Technology Assessment, HTA）的核心不是限制給付，而是確保決策邏輯與證據基礎的一致性」。若決策已選擇限縮適應症，即代表已隱含認可該族群之臨床效益；不宜再對同一族群反覆提高或追加證據要求，否則實質上將形成以證據名義進行給付限縮的情形，並建議參考英國NICE制度，台灣應積極規劃導入「範疇界定（scoping）」與早期預警機制，並強化病人與專家參與，以提升決策品質與透明度。
蒲若芳的CV
蒲 若 芳
輔仁大學 數據科學中心 執行長
台北醫學大學醫務管理學系所 兼任助理教授
地址：新北市新莊區中正路510號 輔仁大學 國璽樓
MD380
聯絡電話：02-
2905 6494
更新日期: 2025 -8 - 27
A.
學歷
1991 臺灣大學公共衛生學系畢業
1993 臺灣大學公共衛生研究所流行病學組碩士 (MS)
2002 臺灣大學流行病學研究所流行病學組博士 (PhD)
B.
經歷
|
2023.4~迄今 |
輔仁大學數據科學中心執行長 |
|
|
2017.9~迄今 |
輔仁大學兼任助理教授 |
|
|
2016.12~2023.1 |
衛生福利部國家C型肝炎旗艦計畫辦公室（2019年12月改名為衛生福利部國家消除C肝辦公室） 主任 |
|
|
2015.9~2016.8 |
臺灣大學健康資料研究中心 資深研究員 |
|
|
2010.7~2015.8 |
財團法人醫藥品查驗中心醫藥科技評估組組長 |
|
|
2009.12~2010.6 |
財團法人醫藥品查驗中心醫藥科技評估組代組長 |
|
|
2007.9~2009.11 |
財團法人醫藥品查驗中心醫藥科技評估組研究員 |
|
|
2006~迄今 |
台北醫學大學醫務管理學系所 兼 |
|
|
1999~2007 |
日祥醫事管理顧問股份有限公司 研究總監 |
|
|
|
|
|
|
C.
諮詢 |
|
|
|
2019 |
國家衛生研究院論壇108年研究主題 「預防接種服務財務解決對策」委員會委員 |
|
|
2019.1~ |
聯愛工程HTA中心學術顧問委員會委員 |
|
|
2019~2020 |
衛生福利部社保司「全民健保醫療給付費用總額基期費用檢討」工作小組 |
|
|
2014~2015,
2017~2021, 2024~ |
疾病管制署諮詢委員 |
|
|
2020.2~2023.2,
2024.2~2028.1 |
癌症希望基金會學術委員 |
|
|
|
|
|
|
|
|
|
D. 學會參與
|
2026~ 2025~2027 2025~ |
HTAi Business Development Committee member ISPOR Awards Council Marilyn Dix Smith Award Subcommittee Member of the 19th Medical Committee of the Gastroenterological Society
of Taiwan |
|
2024~ |
(ISPOR) Value in Health Regional Issues Editorial Board member |
|
2023~ |
President, Health Outcomes and Technology Teaching and Education Alliance
(HOTTEA) |
|
2021 2019~2020 |
HTAi Policy Forum Advisory Committee Member, International Scientific Program Committee, HTAi 2020 |
|
Member, Program Committee (Public Health), 2020 ISVHLD Global
Hepatitis Summit |
|
|
2018~2021 |
Board of Director, International Society International Society For
Pharmacoeconomics and Outcomes Research (ISPOR) |
|
2018~2019 |
Co-Chair, International Scientific Program Committee, HTAi 2019 |
|
2014~2016 |
International Organizing Committee, Prince
Mahidol Award Conference 2016 |
|
2015~2016 |
President, HTAsiaLink |
|
2011~2019 |
Board, HTAsiaLink |
|
2010~2012 |
INAHTA Board Director |
|
2006~2012 |
Supervisory board member, Taiwan
Society for Pharmacoeconomics and Outcomes (TASPOR) |
|
2003~2006 |
Board member, TASPOR |
E.
近期跨國研究參與
1. DIGI‑HTA Asia working group member (since 2025)
2. HTA guideline Project (A stepwise guide for HTA guideline development), initiated by HITAP International Unit (HIU), National University of Singapore (NUS), and KEMRI Wellcome Trust.
3.
RWE for HTA in
Asia (REALISE) Working Group, initiated by Saw
Swee Hock School of Public Health and HITAP.
(2019-2020)
4.
APAC Liver Disease Alliance.
5. HTA for All.
6. Advisory Panel of “Redundancy in HRQoL algorithms: conceptual and empirical challenges”
F.
近期國內研究或倡議參與
1.
立法院厚生會「罕見疾病權益促進委員會」委員 (2024.11.28-2026.12.31)
2.
立法院厚生會「提升台灣癌症新藥可近性委員會」第二屆學術委員
3.
智慧病人領袖學院院長
4.
癌症希望基金會學術研究委員會 (2024-2028)
5.
「罕見疾病創新治療及藥物給付政策白皮書」計畫共同主持人
(2023)
6.
國家衛生研究院論壇「健保藥物給付多重決策模式」研究參與
(2023)
7.
「臺灣子宮頸癌篩檢政策建言書」撰寫參與
代表性HTA相關著作
n
楊雯雯、鄭燕淑、蒲若芳（2024）。罕見疾病藥物納保審查機制與改革方向。月旦醫事法報告，202406 (92期)，127-147。
n
Pwu RF, Cheng YS, Yang WW, Wu GH.
The Development of Health Technology Assessment in Taiwan: Perspectives and
Analysis. Health Syst Reform. 2023 Dec 31;9(3):2330396. doi:
10.1080/23288604.2024.2330396. Epub 2024 May 7. PMID: 38715195.
n
Yang WW, Juan YC, Wu GHM, Pwu RF. The
Critical Intersect of Regulations, Health Technology Assessment, and Drug
Safety Assessments. Drug Saf (2023). https://doi.org/10.1007/s40264-023-01386-1
n Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH,
Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J,
Mullins CD, Petrou S, Pwu RF, Staniszewska S.
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022
Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices
Task Force. Value Health. 2022; 25: 10-31.
n Besley, S., Cole,
A., Pwu, R., Hsieh, C. (2023) Real-World Evidence: Current Best
Practice for Reimbursement Decision-Making. OHE Contract Research. Available
from
https://www.ohe.org/publications/real-world-evidence-current-best-practicebursement
Decision-Making. OHE Contract Research. Available from https://www.ohe.org/publications/real-world-evidence-current-best-practice
G.
期刊同儕審閱參與
u
Journal of
Hepatology
u
Value in
health
u
Value in
health regional issue
u
Cephalalgia
u
International
Journal of Technology Assessment in Health Care
u
BJOG
u
JFMA
u
JGH
u
Journal of
Oncology
u
Vaccine
u
PLOS ONE
u
Frontiers
u
Public Health
in Practice
u
Health Systems
and Reform
u
Asia Pacific
Journal of Public Health
u Dentist
u
The Lancet
Regional Health – Southeast Asia
H. 論文著作
l Pwu RF, Yang WW, Wu GH, Lu SN, Chien RN. Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan. J Formos Med Assoc. 2025 Dec;124 Suppl 2:S141-S148. doi: 10.1016/j.jfma.2025.11.014. Epub 2025 Nov 14. PMID: 41241630.
l Tsai Y-L, Yang W-W, Wu GH-M, Lin S-C, Tang C-H, Pwu R-F. Evaluation of implementation of patient involvement in Taiwan’s pharmaceutical reimbursement decision-making process. International Journal of Technology Assessment in Health Care. 2025;41(1):e55. doi:10.1017/S026646232510038X
l Kudo, M., Oanh, B. T., Chen, C.-J., Ngat, D. T., George, J., Kim, D. Y., Pimsawadi, L., Tangkijvanich, P., Pwu, R.-F., Mohamed, R., Bunnag, S., Lu, S.-N., Kudtiyakarn, S., Kanto, T., Piratvisuth, T., Wu, C.-C., & Sarno, R., on behalf of the APAC Liver Disease Alliance. (2025). Roadmap for HCC Surveillance and Management in the Asia Pacific. Cancers, 17(12), 1928. https://doi.org/10.3390/cancers17121928
l Norman, R., Roudijk, B., Jonker, M., Stolk, E., Knies, S., Pwu, R.F., O’Neill, C., Howard, K., Devlin, N. A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete. PharmacoEconomics (2025). https://doi.org/10.1007/s40273-025-01476-1
l
Chen, W. J., Chung, Y. C. E., Tseng, C. I.,
Wang, S. C., Huang, C. L., Chen, L. Y., & Pwu, R. F. (2025). Opioid
Substitution Therapy Programs and the National Campaign to Eliminate Hepatitis
C Virus in Taiwan: Current Status and Perspectives in a 2022 National Survey
Among Medical Institutions. Drug and Alcohol Dependence, 267, 111489.
l
Chung Y-CE, Tseng C-I, Wang S-C, Huang C-L,
Chen L-Y, Pwu R-F, Lin C-CC, Chung A-N, Lin J-S, Chen WJ. Opioid agonist
treatment programs and hepatitis C virus elimination in Taiwan: Ways of
expanding the care cascade in screening and treatment. Int J Drug Policy 2024;
134:104658.
l 楊雯雯、鄭燕淑、蒲若芳（2024）。罕見疾病藥物納保審查機制與改革方向。月旦醫事法報告，202406 (92期)，127-147。
l Pwu RF, Cheng YS, Yang WW, Wu GH. The Development of Health Technology Assessment in Taiwan: Perspectives and Analysis. Health Syst Reform. 2023 Dec 31;9(3):2330396. doi: 10.1080/23288604.2024.2330396. Epub 2024 May 7. PMID: 38715195.
l
楊雯雯、吳慧敏、劉嘉玲、鄭國本、余明隆、蒲若芳、盧勝男、簡榮南（2023）。C型肝炎病毒抗體快篩試劑的運用。台灣公共衛生雜誌，42(6)，594-611。
l
Yang WW, Juan YC, Wu GHM, Pwu RF. The Critical Intersect of
Regulations, Health Technology Assessment, and Drug Safety Assessments. Drug
Saf (2023). https://doi.org/10.1007/s40264-023-01386-1
l
Rong-Nan Chien, Sheng-Nan Lu, Grace Hui-Min Wu, Wen-Wen Yang, Raoh-Fang
Pwu, Chia-Ling Liu, Kuo-Pen Cheng, Shih-Chung Chen, Chien-Jen Chen, Policy and
Strategy for Hepatitis C Virus Elimination at the National Level: Experience in
Taiwan, The Journal of Infectious Diseases, Volume 228, Issue Supplement_3, 15
September 2023, Pages S180–S188, https://doi.org/10.1093/infdis/jiad016
l
Chen CC, Lai CH, Chang CL, Cheng WF, Pwu RF, Tsai J, Wang PH,
Whang-Peng J, Lai GM, Managing the transition in cervical screening methods for
Taiwan: Policy recommendations and perspectives, Journal of the Formosan
Medical Association, 2023, (in press) https://doi.org/10.1016/j.jfma.2023.06.018.
l
楊雯雯、劉嘉玲、吳慧敏、鄭國本、盧勝男、簡榮南、蒲若芳. 推動消除C肝政策之回顧. 台灣衛誌；2023:42(2):165-179.
l
KC, S., Lin, L. W., Bayani, D. B. S., Zemlyanska, Y., Adler,
A., Ahn, J., Chan, K., Choiphel, D., Genuino-Marfori, A. J., Kearney, B., Liu,
Y., Nakamura, R., Pearce, F., Prinja, S., Pwu, R., Shafie, A. A., Sui,
B., Suwantika, A., Tunis, S., Wu, H., Zalcberg, J., Zhao, K., Isaranuwatchai,
W., Teerawattananon, Y., & Wee, H. (2023). What, Where, and How to Collect
Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement
Decision-Making in Asia: A reflection into the Past and A Way Forward. International
Journal of Health Policy and Management, 12(1), 1-9. doi:
10.34172/ijhpm.2023.6858
l
Shiroiwa,
T., Murata, T., Ahn, J., Li, X., Nakamura, R., Teerawattananon, Y., Kun, Z.,
Shafie, A. A., Valverde, H., Lam, H., Ng, K., Nadjib, M., Pwu, R. F.,
Nugraha, R. R., Chen, Y. C., & Fukuda, T. (2022). Developing a New
Region-Specific Preference-Based Measure in East and Southeast Asia. Value
in health regional issues, 32, 62–69. https://doi.org/10.1016/j.vhri.2022.07.002
l
楊雯雯、吳慧敏、盧勝男、劉嘉玲、鄭國本、蒲若芳. 滾動調整2025年C肝消除治療目標數. 台灣衛誌；2022:41(6):567-71.
l Husereau D, Drummond M,
Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L,
Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu
RF, Staniszewska S.
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)
Statement: Updated Reporting Guidance for Health Economic Evaluations. Value
Health. 2022; 25: 3-9.
l Husereau D, Drummond M,
Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L,
Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu
RF, Staniszewska S.
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022
Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices
Task Force. Value Health. 2022; 25: 10-31.
l Lu
CY, Tang CH, Fu T, Pwu RF, Ho YF. Pneumococcal conjugate vaccines in
Taiwan: Optimizing health gains in children and older adults through
constrained optimization modeling: Pneumococcal conjugate vaccines optimization
in Taiwan. Int J Infect Dis. 2021. Nov 5;S1201-9712(21)00851-1. doi: 10.1016/j.ijid.2021.10.058.
l Chien RN, Lu SN, Pwu RF, Wu GH, Yang WW, Liu CL. Taiwan accelerates
its efforts to eliminate hepatitis C. Glob Health Med. Released July 05, 2021.
Online ISSN 2434-9194. Doi:https://doi.org/10.35772/ghm.2021.01064.
l Wu GHM, Yang WW, Liu CL, Pwu RF, Chien RN, Lee PC, Chen SC, Chen DS,
Lu SN. The epidemiological profile of chronic hepatitis C with advanced hepatic
fibrosis regarding virus genotype in Taiwan: A nationwide study. J Formos Med
Assoc, 2021; 120: 1444-51.
l Lou J, KC S, Toh K, Dabak S, Adler A, Ahn J, Bayani D, Chan K, Choiphel D,
Chua B, Genuino AJ, Guerrero AM, Kearney B, Lin LW, Liu Y, Nakamura R, Pearce
F, Prinja S, Pwu RF, Shafie AA, Sui B, Suwantika A, Teerawattananon Y,
Tunis S, Wu HM, Zalberg J, Zhao K, Isaranuwatchai W, Wee HL. Real-world data
for health technology assessment for reimbursement decisions in Asia: Current
landscape and a way forward. International Journal of Technology Assessment in
Health Care. 2020, 1-7. doi:10.1017/S0266462320000628
l Shiv K Sarin, Manoj Kumar, Mohammed Eslam, Jacob George, Mamun Al Mahtab,
Sheikh M Fazle Akbar, Jidong Jia, Qiuju Tian, Rakesh Aggarwal, David H Muljono,
Masao Omata, Yoshihiko Ooka, Kwang-Hyub Han, Hye W Lee, Wasim Jafri, Amna S
Butt, Chern H Chong, Seng G Lim, Raoh-Fang Pwu, Ding-Shinn Chen. Liver
diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology
Commission. The Lancet Gastroenterology & Hepatology. 2020;5(2):167-228. https://doi.org/10.1016/S2468-1253(19)30342-5
l
劉嘉玲、楊雯雯、吳慧敏、鄭國本、蒲若芳. 臺灣 C 型肝炎消除的國家政策與軌跡. 愛之關懷. 2019;109:6-16.
l Teerawattananon Y, Rattanavipapong W, Lin L, Dabak S, Gibbons B,
Isaranuwatchai W, Toh K, Cher B, Pierce F, Bayani D, Nakamura R, Pwu
R, Shafie A, Adhikari D, Prinja S, Babidge, W. Landscape analysis of
health technology assessment (HTA): Systems and practices in
Asia. International Journal of Technology Assessment in Health Care,
2019;35(6):416-421. doi:10.1017/S0266462319000667
l
從英國發展早期感知與預警系統的經驗為例，看台灣健康照護體系之應用. 楊雯雯、蒲若芳. 台灣衛誌 2019；38(3)：236-251.
l Teerawattananon Y, Luz K, Yothasmutra C, Pwu RF, Ahn J, Shafie AA,
Chalkidou K, Tantivess S, Santatiwongchai B, Rattanavipapong W, Dabak S. HISTORICAL
DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF
SUCCESS. International Journal of Technology Assessment in Health
Care, 2018;34(3), 260-266. doi:10.1017/S0266462318000223
l Shantakumar S, Pwu RF, D’Silva L, Wurst K, Kuo YW, Yang YY, Juan
YC, Chan KA. Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide
population-based study. BMC Pulm Med. 2018;18(1):16
l Wu GH, Pwu RF, Chen SC. Achieving hepatitis C elimination
in Taiwan-Overcoming barriers by setting feasible strategies. J Formos Med
Assoc, 117 (2018), pp. 1044-1045
l Hailey D, Werko S, Rosen M, Macpherson K, Myles S, Gallegos Rivero V,
Hipolito-Olivares C, Sihvo S, Pwu RF, Yang WW, Chen YC, Perez Galan A,
Aleman A, Villamil E. Influence of Health Technology Assessment and Its
Measurement. Int J Technol Assess Health Care 2016;32(6): 376-384.
l Chiu WT, Pwu RF, Gau CS. Affordable health technology assessment in
Taiwan: A model for middle-income countries. J Formos Med Assoc.
2015;114(6):481-3.
l Soon SS, Lopes G, Lim HY, Wong-Rieger D, Bahri S, Hickinbotham L, Jha A,
Ko BS, MacDonell D, Pwu RF, Shih R, Sirachainan E, Suh DC, Wale J, Zhang X, Wee
HL. A call for action to improve access to care and treatment for patients with
rare diseases in the Asia-Pacific region. Orphanet J Rare Dis. 2014; 9: 137.
l Tan EC, Pwu RF, Chen DR, Yang MC. Is a diabetes pay-for-performance
program cost-effective under the National Health Insurance in Taiwan? Qual Life
Res. 2014;23(2):687-96.
l Hailey D, Werko S, Bakri R, Cameron A, Gohlen B, Myles S, Pwu RF, Yothasamut J. Involvement of consumers in
health technology assessment activities by Inahta agencies. Int J Technol
Assess Health Care. 2013;29(1): 79-83.
l Aljunid SM, Srithamrongsawat S, Chen W, Bae SJ, Pwu RF, Ikeda S, et
al. Health-Care Data Collecting, Sharing, and Using in Thailand, China
Mainland, South Korea, Taiwan, Japan, and Malaysia. Value in health.
2012;15(1):S132-S8.
l Chow IH, Tang CH, You SL, Liao CH, Chu TY, Chen CJ, Chen CA, Pwu RF.
Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear
for cervical cancer screening in a publicly financed health-care system. Br J
Cancer 2010;103:1773-82.
l Pwu RF, Liu CY, Ko SY, Tsai IC,
Yang YK. Pharmacoeconomic evaluation of paliperidone extended release versus
olanzapine or quetiapine in the treatment for patients with schizophrenia in
Taiwan. Taiwanese Journal of Psychiatry [Taipei] 2010; 24: 281-91.
l Liao CH, Liu JT, Pwu RF, You SL, Chow I, Tang CH. Valuation of the
economic benefits of human papilomavirus vaccine in Taiwan. Value in Health,
2009, 12(S3), S74-77.
l Tang CH, Pwu RF, Tsai IC, Wang HI, You SL, Chen CA, Scuffham PA,
Hsieh CY, Chou CY, Lin SR, Chen YD, Chen CJ. Costs of cervical cancer and
precancerous lesions treatment in a publicly financed health care system. Arch
Gynecol Obstet 2009.
l Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha, EH. The
cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Asian Pacific J Cancer Prev 2008; 9 (3): 459-566.
l Lacey L, Chien RN, Chuang WL, Pwu RF. Economic evaluation of
chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol. Apr
2008;23(4):571-579.
l Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs
suspected of being associated with Stevens-Johnson syndrome and toxic epidermal
necrolysis: a case-control study. Internal Medicine Journal 2005;
35 (3):188-190.
l Wang SJ, Fuh JL, Juang KD, Lu SR, Hsu LC, Chen WT, Pwu RF.
Evolution of migraine diagnosis in adolescents: a 3-year annual survey.
Cephalalgia 2005; 25(5):333-8.
l Hsu HC, Pwu RF. Too Late to Quit? Effect of Smoking and Smoking
Cessation on Morbidity and Mortality Among the Elderly in a Longitudinal Study.
The Kaohsiung Journal of Medical Sciences 2004; 20(10):484-91.
l Fuh JL, Pwu RF, Wang SJ, Chen YH. Measuring Alzheimer’s Disease
Progression with Transition Probabilities in the Taiwanese Population.
International journal of geriatric psychiatry 2004; 19(3):266-70.
l Pwu RF, Chan KA.
Cost-effectiveness analysis of interferon-alpha therapy in the treatment of
chronic hepatitis B in Taiwan. J Formos Med Assoc 2002;101:632-41.
l Chen CJ, You SL, Pwu RF, Wang LY, Lin YP, Hsi GC, Hsi MS, Ho
HC, Lee CT, Lin CG and et al. Community-based cervical cancer screening in
seven townships in Taiwan. Journal of the Formosan Medical Association 1995;94
:S103-11
I.
專書篇章
1.
蒲若芳、楊雯雯、吳慧敏。追求分配正義建立臺灣NICE。載於黃煌雄、江東亮（主編）， 第三波健保改革之路（頁137-164）。台北市：遠見天下文化
2.
湯澡薰、吳慧敏、蒲若芳。健康經濟與經濟評估。載於吳肖琪、鄭守夏(編輯)，衛生行政與管理。台北市：財團法人陳拱北醫學基金會
J.
Research Reports
1.
Besley, S., Cole, A., Pwu, R., Hsieh, C. (2023) Real-World
Evidence: Current Best Practice for Reimbursement Decision-Making. OHE Contract
Research. Available from
https://www.ohe.org/publications/real-world-evidence-current-best-practicebursement
Decision-Making. OHE Contract Research. Available from https://www.ohe.org/publications/real-world-evidence-current-best-practice
2.
罕見疾病創新治療及藥物給付建言書. (2023) 蔡輔仁、曾敏傑、蒲若芳、楊銘欽、陳莉茵、簡穎秀、蔡甫昌。財團法人罕見疾病基金會。
訂閱：
意見 (Atom)